Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Financing
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Feb 20, 2021 11:32am
267 Views
Post# 32618625

RE:RE:RE:RE:RE:Financing

RE:RE:RE:RE:RE:Financing
Marky1 wrote: Burt...you just fell off my intelligency list...Down at the bottom with abc


Marky, he's only been here since December 2020 and he's been making really odd comments.  A little digging reveals that he follows the one stock he's following at any given time.  He guesses alot and he critsizes alot.  I've put him on ignore and I suggest you do the same.

Remember this recent comment from him ...

---------------------

Well......... sorry just f*g with u! But you really don't believe an update is coming, do you? I mean they are obviously A - selling the company B - selling the drug C - a licensing deal Why give an update when we are on the verge of exiting this investment. It wouldn't make any sense.

-------------------

A few days later we received the Investor update.  

So, he's either playing us or he has no idea.

He has no idea that you have been a very good source of information for this team. 
Just ignore him Marky !!!!



<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities